What TScan Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 3 |
| Sells | 0 | 0 |
| Total trades | 2 | 5 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 81,732 |
| Disposed | 0 | 0 |
| Net activity | +0 | +81,732 |
Common stock only — 3 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Zdraveski Zoran | See Remarks | Oct 01 | Grant / award · A | +300,000 | — | — | 304,716 |
| MacBeath Gavin | Chief Executive Officer | Oct 01 | Grant / award · A | +1,000,000 | — | — | 1,049,767 |
| Lynx1 Capital Management Lp | 10% owner | Dec 23 | Open-market buy · P | +6,232 | $0.90 | +$5.6K | 8,019,148 |
| Lynx1 Capital Management Lp | 10% owner | Dec 22 | Open-market buy · P | +75,500 | $0.90 | +$68K | 8,012,916 |
| Lynx1 Capital Management Lp | 10% owner | Dec 19 | Open-market buy · P | +80,069 | $0.90 | +$72K | 7,937,416 |
| Lynx1 Capital Management Lp | 10% owner | May 20 | Open-market buy · P | +1,200,000 | $1.20 | +$1.44M | 7,946,141 |
| Lynx1 Capital Management Lp | 10% owner | May 19 | Open-market buy · P | +1,388,794 | $1.20 | +$1.67M | 6,746,141 |
| Lynx1 Capital Management Lp | 10% owner | Dec 13 | Open-market buy · P | +100,000 | $2.90 | +$290K | 5,357,347 |
| Lynx1 Capital Management Lp | 10% owner | Dec 12 | Open-market buy · P | +31,800 | $3.01 | +$95.6K | 5,257,347 |
| Lynx1 Capital Management Lp | 10% owner | Nov 15 | Open-market buy · P | +947 | $4.34 | +$4.11K | 5,225,547 |
| Klencke Barbara | Director | Sep 23 | Open-market buy · P | +5,000 | $5.29 | +$26.5K | 45,000 |
| Klencke Barbara | Director | Aug 26 | Open-market buy · P | +5,000 | $5.53 | +$27.7K | 40,000 |
| Klencke Barbara | Director | Aug 23 | Open-market buy · P | +5,000 | $5.69 | +$28.5K | 35,000 |
| Zdraveski Zoran | See Remarks | Aug 23 | Exercise / conversion · M | +64,166 | $2.49 | +$160K | 169,402 |
| Zdraveski Zoran | See Remarks | Aug 23 | Exercise / conversion · M | +13,125 | $1.81 | +$23.8K | 105,236 |
| Zdraveski Zoran | See Remarks | Aug 23 | Exercise / conversion · M | +25,000 | $3.27 | +$81.8K | 92,111 |
| Zdraveski Zoran | See Remarks | Aug 23 | Exercise / conversion · M | +54,895 | $4.85 | +$266K | 67,111 |
| Zdraveski Zoran | See Remarks | Aug 23 | Open-market sale · S | −164,686 | $5.78 | −$952K | 4,716 |
| Barberich Timothy J | Director | Dec 19 | Open-market buy · P | +317 | $4.97 | +$1.58K | 67,027 |
| Barberich Timothy J | Director | Dec 18 | Open-market buy · P | +28,830 | $4.89 | +$141K | 66,710 |
Loading...